PacBio Agrees To Pay $800M For Omniome To Add Complementary Short-Read Sequencing Platform
Executive Summary
Pacific Biosciences has agreed to pay $600m upfront in cash and stock and up $200m in additional milestone payments to acquire Omniome. PacBio also announced a new private placement of common stock to raise $300m.
You may also be interested in...
Invitae Claws At $50m, Selling Reproductive Health Assets
Natera has pounced on the opportunity to purchase Invitae’s reproductive health assets at a bargain price, simultaneously quashing any potential ongoing royalty payments between the two.
PacBio Scores Hat Trick Of Big News To Start August
A jump in earnings, the acquisition of Apton and the launch of the long-awaited Onso sequencing system – all in one week at Pacific Biosciences.
Dealmaking Quarterly Statistics, Q3 2021
In the third quarter of 2021, medical device company M&A values reached $7.1bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $6.7bn.